 |
|
|
|
November 2003 Cover
|
|
In a five-year study, most patients using Abbott Laboratories' HIV drug Kaletra achieved and maintained undetectable viral levels and did not develop drug resistance. Abbott said the data demonstrate that undetectable viral
levels can be maintained when Kaletra is administered with two other drugs.
In the study of 100 patients, 67 of 68 patients who took the medications as an initial treatment and remained on the treatment for 252 weeks had undetectable levels of the virus. Patients in the study took Kaletra along
with GlaxoSmithKline's lamivudine and Bristol-Myers Squibb's stavudine-- two nucleoside analogues. Kaletra is the most prescribed protease inhibitor in the United States and Europe.
Editor's Note: from the Chicago Sun-Times
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
